Drug intelligence / Profile preview

senrebotase

Development stage
Phase 2
Lead developer
AbbVie
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Injection
01

Overview

Senrebotase is an engineered botulinum neurotoxin derivative developed for the treatment of overactive bladder and postherpetic neuralgia. It is a recombinant protein designed to target specific neuronal pathways involved in these conditions. The drug acts as an antagonist at nociceptin/orphanin FQ peptide (OOR) receptor and soluble NSF attachment protein receptor (SNARE) complex, thereby inhibiting neurotransmitter release and modulating pain or bladder function. Senrebotase completed phase 2 clinical trials for overactive bladder syndrome and postherpetic neuralgia but was discontinued before approval. The original developer was Health Protection Agency Porton Down1, with later development by Allergan UC (now part of AbbVie). Its modality is classified as a peptide/protein therapeutic administered by injection[1][2][3][5][7].

Other names
senrebotase
02

Targets

NOP (Nociceptin/orphanin FQ peptide receptor)VAMP (SNARE Protein Complex)

Beyond the preview

Go deeper on senrebotase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on senrebotase.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call